Program 1
Next-generation CAR T candidate with tumor-selective targeting for hematological malignancies.
Pipeline
Our investigational therapies and development strategy
Celyad Oncology USA is advancing a pipeline of CAR T-cell candidates designed for both hematological and solid tumor applications. Our programs focus on innovative receptor designs, safety controls, and broader patient access.
Program 2
Solid tumor CAR T therapy designed to overcome the tumor microenvironment and enhance persistence.
Program 3
Clinical development program combining safety features with scalable manufacturing and patient support.